http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2892624-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-044 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5383 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4196 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5383 |
| filingDate | 2016-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ebb0b194e5f064bcd78764b9bbe3c9cf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49f76e6603a850a5bcd07d94db9e383b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e84b33323958c157d9959b970cab39a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8faffe20c3127ef5c1a4b3206c4df81d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_578ce04bbe14fa95878f01a33081ac86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e4447b097cc54bb43b3cc562da3079c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c05fea065691d138c346911458141c4b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1c87bba04af85a39531e45c5ff1b0cc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08875fa89cac664543f103097de3ac27 |
| publicationDate | 2022-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2892624-T3 |
| titleOfInvention | Tricyclic compounds and compositions as kinase inhibitors |
| abstract | A compound of formula (A): **(See formula)** in which: R' is selected from H and methyl; R1 is C1-3 alkyl substituted with CN or with one or more halogens; R2 is selected from: **(See formula)** where Y6 is selected from N and CH; Z1 is CR3R4 or a bond; and Z2 is CR5R6, -C(O)NR8-[Y6], or -NR8C(O)-[Y6], where [Y6] indicates which atom of Z2 is bonded to the ring containing Y6; R3 is selected from hydrogen, C1-3alkyl, halo, C1-3alkylaminocarbonyl, C1-3alkyl-S(O)0-2-C1-2alkyl, carboxyl, and hydroxy-substituted C1-3alkyl; R4 is selected from hydrogen, amino, C1-3 alkyl, cyano, hydroxyethyl, and halo; or R3 and R4 together with the carbon atom to which R3 and R4 are attached form a 4-membered saturated cyclic ring containing one molecule of oxygen; R5 is selected from hydrogen, halo, amino, C1-3 alkylamino-carbonyl, C1-3 alkylcarbonyl, hydroxy, and C1-3 alkoxy; R6 is selected from hydrogen, C1-3 alkyl, halo, halo-substituted C1-3 alkyl; or R4 and R6 together with the carbon atom to which R4 and R6 are attached form a 5-6 membered unsaturated ring containing up to 2 heteroatoms selected from O, S and N; wherein said ring is optionally substituted with C1-2alkyl; R8 is selected from hydrogen, C1-3alkylaminocarbonyl, C1-3alkylcarbonyl, C1-3alkoxy and hydroxy-substituted C1-4alkoxy, hydroxy-substituted C1-3alkyl, and C1-3alkyl; R9 is independently selected at each occurrence from hydrogen, fluorine, and methyl; Y0 is selected from N, CH and CF; Y1 is selected from N and CH; Y2 is selected from N, CH, CF, CCl, C-NH2 and C-C(R9)2NH2; Y3 is selected from N and CH; Y4 is selected from N and CH; or a pharmaceutically acceptable salt thereof. |
| priorityDate | 2015-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 996.